

Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/F7C277D1CF88EN.html>

Date: January 2022

Pages: 70

Price: US\$ 2,000.00 (Single User License)

ID: F7C277D1CF88EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Fms-like tyrosine kinase 3 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Fms-like tyrosine kinase 3 inhibitors Understanding

Fms-like tyrosine kinase 3 inhibitors: Overview

FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase (RTK), a membrane-bound receptor with an intrinsic tyrosine kinase activity that is highly expressed in hematopoietic stem/progenitor cells and regulates hematopoietic differentiation and proliferation. Activation and mutation of FLT3 is closely implicated in the occurrence and development of acute myeloid leukemia (AML). FLT3 is made up of 5 functional domains: an immunoglobulin-like extracellular domain, a transmembrane domain, a juxtamembrane domain (JMD), a tyrosine kinase domain (TKD), and a small C-terminal domain. FLT3 is a promising molecular target in a subset of AML cases, and the

therapeutic effects of FLT3 inhibitors have been reported in AML patients with FLT3 mutations. The exploration of small-molecule inhibitors targeting FLT3 has aroused wide interest of pharmaceutical chemists and is expected to bring new AML therapy. A number of resistance mechanisms to FLT3 inhibitors have been identified in preclinical and clinical studies, including acquired FLT3 resistance mutations, other gene mutations such as NRAS, and altered protein expression such as that of FL, AXL kinase, Pim kinase, or FGF2.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Fms-like tyrosine kinase 3 inhibitors R&D. The therapies under development are focused on novel approaches for Fms-like tyrosine kinase 3 inhibitors.

Fms-like tyrosine kinase 3 inhibitors Emerging Drugs Chapters

This segment of the Fms-like tyrosine kinase 3 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fms-like tyrosine kinase 3 inhibitors Emerging Drugs

CG-806: Aptose Biosciences

CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor. This small molecule, in-licensed from CrystalGenomics in Seoul, South Korea, demonstrates potent inhibition of wild type and all mutant forms of FLT3 (including internal tandem duplication, or ITD, and mutations of the receptor tyrosine kinase domain and gatekeeper region), cures animals of acute myeloid leukemia (AML) tumors in the absence of toxicity in murine xenograft models. The drug is in Phase I/II clinical studies for the treatment of CLL & NHL.

Quizartinib: Daiichi Sankyo Company

Quizartinib is an orally administered, small molecule FLT3 kinase inhibitor. Quizartinib was approved by the Ministry of Health, Labor and Welfare (MHLW) of Japan under the brand name of VANFLYTA for the treatment of adult patients with relapsed/refractory FLT3-ITD AML on June 18, 2019. Quizartinib is currently being studied alone or in combination with other agents as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in adult and pediatric populations.

Further product details are provided in the report.....

Fms-like tyrosine kinase 3 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Fms-like tyrosine kinase 3 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Fms-like tyrosine kinase 3 inhibitors

There are approx. 25+ key companies which are developing the Fms-like tyrosine kinase 3 inhibitors. The companies which have their Fms-like tyrosine kinase 3 inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Quizartinib.

Phases

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Fms-like tyrosine kinase 3 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fms-like tyrosine kinase 3 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Fms-like tyrosine kinase 3 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fms-like tyrosine kinase 3 inhibitors drugs.

Fms-like tyrosine kinase 3 inhibitors Report Insights

Fms-like tyrosine kinase 3 inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Fms-like tyrosine kinase 3 inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Fms-like tyrosine kinase 3 inhibitors drugs?

How many Fms-like tyrosine kinase 3 inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Fms-like tyrosine kinase 3 inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fms-like tyrosine kinase 3 inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Fms-like tyrosine kinase 3 inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Aptose Biosciences

Daiichi Sankyo Company

Celon Pharma

AROG Pharmaceuticals

Pfizer

Ascentage Pharma

Pharos I&BT Co

Novartis Oncology

Exelixis

Ipsen

Key Products

CG-806

Quizartinib

Research program: small molecule anti-cancer therapeutics

Crenolanib

Olverembatinib

PHI-101

Midostaurin

Cabozantinib

Contents

Introduction

Executive Summary

Fms-like tyrosine kinase 3 inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Fms-like tyrosine kinase 3 inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Fms-like tyrosine kinase 3 inhibitors companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Fms-like tyrosine kinase 3 inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Quizartinib: Daiichi Sankyo Company

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Coltuximab Ravtansine: Sanofi

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

CG-806: Aptose Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

RC58: RemeGen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Fms-like tyrosine kinase 3 inhibitors Key Companies

Fms-like tyrosine kinase 3 inhibitors Key Products

Fms-like tyrosine kinase 3 inhibitors- Unmet Needs

Fms-like tyrosine kinase 3 inhibitors- Market Drivers and Barriers

Fms-like tyrosine kinase 3 inhibitors- Future Perspectives and Conclusion

Fms-like tyrosine kinase 3 inhibitors Analyst Views

Fms-like tyrosine kinase 3 inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Fms-like tyrosine kinase 3 inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Fms-like tyrosine kinase 3 inhibitors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/F7C277D1CF88EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F7C277D1CF88EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970